Automate Your Wheel Strategy on NVAX
With Tiblio's Option Bot, you can configure your own wheel strategy including NVAX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVAX
- Rev/Share 7.7924
- Book/Share -0.4697
- PB -14.1583
- Debt/Equity -3.0229
- CurrentRatio 2.0561
- ROIC 0.46
- MktCap 1077100500.0
- FreeCF/Share -1.2205
- PFCF -5.4798
- PE 2.2373
- Debt/Assets 0.1768
- DivYield 0
- ROE -1.1551
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NVAX | Citigroup | -- | Sell | -- | $6 | June 17, 2025 |
| Initiation | NVAX | BTIG Research | -- | Buy | -- | $19 | Feb. 28, 2025 |
News
Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025
Published: July 30, 2025 by: PRNewsWire
Sentiment: Neutral
GAITHERSBURG, Md. , July 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its second quarter 2025 financial results and operational highlights at 8:30 a.m.
Read More
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novavax (NVAX) concluded the recent trading session at $6.41, signifying a +1.75% move from its prior day's close.
Read More
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Read More
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
Published: June 12, 2025 by: Zacks Investment Research
Sentiment: Positive
NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.
Read More
Novavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Published: June 10, 2025 by: Reuters
Sentiment: Neutral
Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccine panel late on Monday.
Read More
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Here's Why Novavax (NVAX) is a Strong Momentum Stock
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Read More
Analysts Think These Stocks Could More Than Double in Value
Published: May 23, 2025 by: MarketBeat
Sentiment: Negative
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk.
Read More
Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Positive
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the only non-mRNA COVID-19 vaccine with full FDA approval, offering a differentiated alternative amid growing mRNA fatigue. Sanofi partnership brings immediate cash, future royalties, and potential milestone payments from pipeline programs, strengthening Novavax's financial outlook.
Read More
Healthy Returns: Novavax scores narrower Covid vaccine approval after delay
Published: May 20, 2025 by: CNBC
Sentiment: Neutral
The FDA approved Novavax's Covid-19 vaccine but with unusual restrictions.
Read More
Top Stock Movers Now: Tesla, AutoZone, Novavax, and More
Published: May 19, 2025 by: Investopedia
Sentiment: Neutral
U.S. equities were down at midday, while the yield on the 10-year Treasury jumped, as the market reacted to Moody's downgrading the U.S. debt rating. The Dow Jones Industrial Average, S&P 500, and Nasdaq all slid.
Read More
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.
Read More
Novavax Stock Soars on FDA Approval for COVID Vaccine
Published: May 19, 2025 by: Schaeffers Research
Sentiment: Positive
Biotech stock Novavax Inc (NASDAQ:NVAX) is skyrocketing today, up 26% at $8.48 at last glance, after the U.S. Food & Drug Administration (FDA) approved the company's COVID-19 vaccine.
Read More
Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.
Published: May 19, 2025 by: Barrons
Sentiment: Positive
Nuvaxovid had been available under emergency use authorization but the full approval may allow it to better compete with rival vaccine makers.
Read More
Novavax shares surge 26% after FDA grants conditional approval for Covid vaccine
Published: May 19, 2025 by: Proactive Investors
Sentiment: Positive
Novavax, Inc. (NASDAQ:NVAX) shares jumped 26% in premarket trading on Monday after the U.S. Food and Drug Administration granted full approval for its COVID-19 vaccine, though with narrower eligibility than expected.
Read More
U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
Nuvaxovid™ is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S. Biologics License Application approval triggers $175 million Sanofi milestone payment, with additional COVID-19 vaccine milestones and ongoing tiered royalties to be recognized when earned GAITHERSBURG, Md. , May 19, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Nuvaxovid™ for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years and older and individuals 12 through 64 years who have …
Read More
FDA approves Novavax COVID vaccine with new conditions
Published: May 17, 2025 by: Reuters
Sentiment: Neutral
The U.S. Food and Drug Administration on Friday approved Novavax's COVID-19 vaccine, but placed additional conditions on individuals who would be able to receive the vaccine.
Read More
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Positive
Initiate coverage on Novavax with a Buy rating; Q1 2025 marks an inflection point with $519M net income and raised revenue guidance to $975M-$1.025B. Novavax's Q1 2025 revenue surged to $667M, driven by $603M from terminated APA agreements and $19M from new vaccine shipments, indicating strong demand. Sanofi partnership converts lower-margin product revenue to higher-margin income, allowing Novavax to focus on R&D and achieve non-GAAP profitability by 2027.
Read More
Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.
Read More
Novavax, Inc. (NVAX) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Novavax, Inc. (NASDAQ:NVAX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer Ruxandra Draghia-Akli - Executive Vice President, Head of Research and Development Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer John Trizzino - President and Chief Operating Officer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Alec Stranahan - Bank of America Securities Tom Shrader - BTIG Eric Joseph - JPMorgan Chris LoBianco - TD Securities Operator Good morning and welcome …
Read More
Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago.
Read More
Novavax swings to profit on lower expenses related to COVID shots
Published: May 08, 2025 by: Reuters
Sentiment: Positive
Novavax on Thursday swung to a first-quarter profit from a year-ago loss, helped by reduced costs related to the development and sale of its COVID-19 vaccines, its only product on the market.
Read More
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDA SHIELD-Utah study demonstrates that Nuvaxovid® resulted in fewer and less severe reactogenicity symptoms when compared to marketed mRNA vaccine; Nuvaxovid recipients experienced approximately 39% fewer symptoms on average Data presented at World Vaccine Congress showcases Matrix-M ® utility when co-administered with a broad array of vaccine platforms and diseases Strengthened partnership with Takeda in Japan, the third largest pharmaceutical market, with significant improvement in financial terms Raises full year 2025 revenue framework to between $975 million and $1,025 million …
Read More
About Novavax, Inc. (NVAX)
- IPO Date 1995-12-05
- Website https://www.novavax.com
- Industry Biotechnology
- CEO John Charles Jacobs
- Employees 952